Effect of Aspirin vs Enoxaparin on 90-Day Mortality in Patients Undergoing Hip or Knee Arthroplasty: A Secondary Analysis of the CRISTAL Cluster Randomized Trial
- PMID: 37294566
- PMCID: PMC10257098
- DOI: 10.1001/jamanetworkopen.2023.17838
Effect of Aspirin vs Enoxaparin on 90-Day Mortality in Patients Undergoing Hip or Knee Arthroplasty: A Secondary Analysis of the CRISTAL Cluster Randomized Trial
Abstract
Importance: Ischemic heart disease remains the leading cause of mortality following hip and knee arthroplasty. Due to its antiplatelet and cardioprotective properties, aspirin has been proposed as an agent that could reduce mortality when used as venous thromboembolism (VTE) prophylaxis following these procedures.
Objective: To compare aspirin with enoxaparin in reducing 90-day mortality for patients undergoing hip or knee arthroplasty procedures.
Design, setting, and participants: This study was a planned secondary analysis of the CRISTAL cluster randomized, crossover, registry-nested trial performed across 31 participating hospitals in Australia between April 20, 2019, and December 18, 2020. The aim of the CRISTAL trial was to determine whether aspirin was noninferior to enoxaparin in preventing symptomatic VTE following hip or knee arthroplasty. The primary study restricted the analysis to patients undergoing total hip or knee arthroplasty for a diagnosis of osteoarthritis only. This study includes all adult patients (aged ≥18 years) undergoing any hip or knee arthroplasty procedure at participating sites during the course of the trial. Data were analyzed from June 1 to September 6, 2021.
Interventions: Hospitals were randomized to administer all patients oral aspirin (100 mg daily) or subcutaneous enoxaparin (40 mg daily) for 35 days after hip arthroplasty and 14 days after knee arthroplasty procedures.
Main outcomes and measures: The primary outcome was mortality within 90 days. The between-group difference in mortality was estimated using cluster summary methods.
Results: A total of 23 458 patients from 31 hospitals were included, with 14 156 patients allocated to aspirin (median [IQR] age, 69 [62-77] years; 7984 [56.4%] female) and 9302 patients allocated to enoxaparin (median [IQR] age, 70 [62-77] years; 5277 [56.7%] female). The mortality rate within 90 days of surgery was 1.67% in the aspirin group and 1.53% in the enoxaparin group (estimated difference, 0.04%; 95% CI, -0.05%-0.42%). For the subgroup of 21 148 patients with a nonfracture diagnosis, the mortality rate was 0.49% in the aspirin group and 0.41% in the enoxaparin group (estimated difference, 0.05%; 95% CI, -0.67% to 0.76%).
Conclusions and relevance: In this secondary analysis of a cluster randomized trial comparing aspirin with enoxaparin following hip or knee arthroplasty, there was no significant between-group difference in mortality within 90 days when either drug was used for VTE prophylaxis.
Trial registration: http://anzctr.org.au Identifier: ACTRN12618001879257.
Conflict of interest statement
Figures
Similar articles
-
Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.JAMA. 2022 Aug 23;328(8):719-727. doi: 10.1001/jama.2022.13416. JAMA. 2022. PMID: 35997730 Free PMC article. Clinical Trial.
-
Aspirin or enoxaparin for VTE prophylaxis after primary partial, total or revision hip or knee arthroplasty: A secondary analysis from the CRISTAL cluster randomized trial.PLoS One. 2024 Apr 16;19(4):e0298152. doi: 10.1371/journal.pone.0298152. eCollection 2024. PLoS One. 2024. PMID: 38626226 Free PMC article. Clinical Trial.
-
Is Enoxaparin Associated With a Higher Risk of Persistent Wound Drainage Than Aspirin? A Secondary Analysis of Data From the CRISTAL Randomized Trial.Clin Orthop Relat Res. 2023 Jul 1;481(7):1351-1359. doi: 10.1097/CORR.0000000000002544. Epub 2023 Jan 17. Clin Orthop Relat Res. 2023. PMID: 36649465 Free PMC article. Clinical Trial.
-
Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis.Orthop Traumatol Surg Res. 2021 Feb;107(1):102606. doi: 10.1016/j.otsr.2020.04.002. Epub 2020 Jul 4. Orthop Traumatol Surg Res. 2021. PMID: 32631716
-
Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials.JAMA Intern Med. 2020 Mar 1;180(3):376-384. doi: 10.1001/jamainternmed.2019.6108. JAMA Intern Med. 2020. PMID: 32011647 Free PMC article.
Cited by
-
Aspirin as Thromboprophylaxis in Orthopedic Surgery: A Matter of Perspective.Hemasphere. 2023 Jul 20;7(8):e933. doi: 10.1097/HS9.0000000000000933. eCollection 2023 Aug. Hemasphere. 2023. PMID: 37533788 Free PMC article. No abstract available.
-
Aspirin Versus LMWH for Thromboprophylaxis Following Hip or Knee Arthroplasty-Clinical Implications and Budget Impact.Pharmacol Res Perspect. 2025 Aug;13(4):e70147. doi: 10.1002/prp2.70147. Pharmacol Res Perspect. 2025. PMID: 40620160 Free PMC article.
-
Efficacy and safety of aspirin in preventing venous thromboembolism after hip arthroplasty for femoral neck fracture: a noninferiority prospective cohort study.BMC Musculoskelet Disord. 2024 Dec 27;25(1):1079. doi: 10.1186/s12891-024-08213-3. BMC Musculoskelet Disord. 2024. PMID: 39731033 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous